Are you interested in cancer research? Have you ever heard of a guy named Dr. Clay Siegall? If you haven’t heard, then you’re not along. Dr. Clay Siegall is one of the most well-respected names in cancer research. He is the current CEO, president and co-founder of Seattle Genetics. This oncology biotech company just so happens to be at the top of its class in the fight against cancer. Located in Bothell, Washington, this company has around 1,000 employees, it specializes in the development of cancer-breakthrough therapies, and it provides cancer-fighting drugs to over 65 countries.
With so much breaking news in this exclusive field of work, Dr. Siegall is well-informed of any and all changes. Cancer research’s status as of today is very promising. The American Society of Clinical Oncology reports that cancer research of today is delivering much faster treatments. This is great news, especially for the millions of people who suffer with the disease on a daily basis. There are various forms of cancer in society today. The good news is that the Food & Drug Administration has cleared and approved up to 20 new treatments that progressively-fights the various forms of cancer. Thanks to the advanced-technologies of the 21st century, these new therapies can detect any changes at the molecular level in a patients’ free-floating DNA as well as detection in tumors. Research and medications are truly helping to detect and eradicate these dangerous diseases much more effectively than treatments of past eras.
On the other hand, Seattle Genetics’ ADCETRIS drug is technologically advanced, and it yields great results on a consistent basis. As of today, this medication has brought in over $350 million in revenue. Dr. Siegall’s strong passion and principles are paying-off in huge returns as well as paying-off in saving lives. Since ADCETRIS is entered into multiple strategic-licensing deals, the medication is being distributed all over the globe.